<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01926977</url>
  </required_header>
  <id_info>
    <org_study_id>ML28895</org_study_id>
    <secondary_id>20131227</secondary_id>
    <nct_id>NCT01926977</nct_id>
  </id_info>
  <brief_title>Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration</brief_title>
  <official_title>Evaluation of Post Injection Inflammation and Pain After Ranibizumab vs Aflibercept Intravitreal Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arshad Khanani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sierra Eye Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the post injection inflammation and pain seen after
      intravitreal injections of Ranibizumab vs Aflibercept.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase I-II study of post injection pain and inflammation after
      intravitreally administered Ranibizumab and Aflibercept in 100 subjects with Neovascular
      Age-Related Macular Degeneration. We will enroll both treatment experienced ( patients who
      were treated with Lucentis or Eylea, but not Avastin in the past) and treatment naive
      patients ( new onset Neovascular AMD with no history of intravitreal injections).

      The treatment experienced patients will be treated with the intravitreal medication other
      than what they were receiving in the past, for example, patients treated with Lucentis will
      switch to Eylea for study purposes and vice versa.

      Consented, enrolled subjects will receive open-label intravitreal injection of either 0.5mg
      Ranibizumab or 2mg Aflibercept. A standard intravitreal injection protocol will be followed.
      Patients will be reevaluated between 24-48 hours and 5-7 days post injections. A
      non-injecting physician will evaluate the patients for anterior chamber inflammation; this
      physician will be blinded about the specific treatment. Anterior chamber inflammation is
      described as any cell or flare in the anterior chamber. These will be evaluated using
      Standardization of Uveitis Nomenclature (SUN) working group classifications.

      Pain score will be evaluated using a Numerical Rating Scale. Each patient will have a
      standard script verbally read to them at their visit, and asked to rate their pain based on
      this scale.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of Anterior Chamber Inflammation</measure>
    <time_frame>24 to 48 hours (visit #1) and 5 to 7 days (visit #2)</time_frame>
    <description>Evidence of anterior chamber inflammation at visit #1 and #2 using Standardization of Uveitis Nomenclature (SUN)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients With Post Injection Pain Score of One or Higher on Pain Scale</measure>
    <time_frame>24 to 48 hours (visit #1) and 5 to 7 days (visit #2)</time_frame>
    <description>Pain score rated on an 11 point numerical rating from 0-10 ( 0 = no pain, and 10 = worst possible pain) administered to each patient verbally at visit #1 and visit #2. The data below shows number of patients with pain score 1 or greater in each group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Neovascular Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Ranibizumab 0.5mg Intravitreal injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal injection of Ranibizumab 0.5mg once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept 2.0mg Intravitreal injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal Aflibercept 2.0mg once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 0.5mg</intervention_name>
    <description>Patient will receive intravitreal injection of Ranibizumab 0.5mg.</description>
    <arm_group_label>Ranibizumab 0.5mg Intravitreal injection</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept 2.0mg</intervention_name>
    <description>Patients will receive intravitreal injection of Aflibercept 2.0mg.</description>
    <arm_group_label>Aflibercept 2.0mg Intravitreal injection</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to provide informed consent and comply with study assessments for the full
             duration of the study

          2. Age &gt;/= 65 years

          3. New onset Neovascular Age-Related Macular Degeneration or (See No.4)

          4. Previously treated Neovascular Age-Related Macular Degeneration with Lucentis or Eylea
             intravitreal injections

          5. Visual Acuity of 20/400 or better

          6. No history of Post injection pain or inflammation with prior treatments -

        Exclusion Criteria:

          1. History of Endophthalmitis in either eye

          2. Uncontrolled or symptomatic Dry Eye Syndrome

          3. History of Anterior or Posterior Uveitis

          4. History of Post injection pain or inflammation with prior treatments

          5. Recent thromboembolic event(&lt;3 months)

          6. Pregnancy(positive pregnancy test) or Lactation/Premenopausal women not using adequate
             contraception -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arshad M Khanani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sierra Eye Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2013</study_first_submitted>
  <study_first_submitted_qc>August 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2013</study_first_posted>
  <results_first_submitted>December 29, 2015</results_first_submitted>
  <results_first_submitted_qc>February 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2016</results_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sierra Eye Associates</investigator_affiliation>
    <investigator_full_name>Arshad Khanani</investigator_full_name>
    <investigator_title>Vitreo-Retinal Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranibizumab 0.5mg Intravitreal Injection</title>
          <description>Intravitreal injection of Ranibizumab 0.5mg once
Ranibizumab 0.5mg: Patient will receive intravitreal injection of Ranibizumab 0.5mg.</description>
        </group>
        <group group_id="P2">
          <title>Aflibercept 2.0mg Intravitreal Injection</title>
          <description>Intravitreal Aflibercept 2.0mg once
Aflibercept 2.0mg: Patients will receive intravitreal injection of Aflibercept 2.0mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranibizumab 0.5mg Intravitreal Injection</title>
          <description>Intravitreal injection of Ranibizumab 0.5mg once
Ranibizumab 0.5mg: Patient will receive intravitreal injection of Ranibizumab 0.5mg.</description>
        </group>
        <group group_id="B2">
          <title>Aflibercept 2.0mg Intravitreal Injection</title>
          <description>Intravitreal Aflibercept 2.0mg once
Aflibercept 2.0mg: Patients will receive intravitreal injection of Aflibercept 2.0mg.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.3" lower_limit="65" upper_limit="96"/>
                    <measurement group_id="B2" value="80.6" lower_limit="67" upper_limit="95"/>
                    <measurement group_id="B3" value="78.6" lower_limit="65" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evidence of Anterior Chamber Inflammation</title>
        <description>Evidence of anterior chamber inflammation at visit #1 and #2 using Standardization of Uveitis Nomenclature (SUN)</description>
        <time_frame>24 to 48 hours (visit #1) and 5 to 7 days (visit #2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5mg Intravitreal Injection</title>
            <description>Intravitreal injection of Ranibizumab 0.5mg once
Ranibizumab 0.5mg: Patient will receive intravitreal injection of Ranibizumab 0.5mg.</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept 2.0mg Intravitreal Injection</title>
            <description>Intravitreal Aflibercept 2.0mg once
Aflibercept 2.0mg: Patients will receive intravitreal injection of Aflibercept 2.0mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Evidence of Anterior Chamber Inflammation</title>
          <description>Evidence of anterior chamber inflammation at visit #1 and #2 using Standardization of Uveitis Nomenclature (SUN)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inflammation at visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inflammation at visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Post Injection Pain Score of One or Higher on Pain Scale</title>
        <description>Pain score rated on an 11 point numerical rating from 0-10 ( 0 = no pain, and 10 = worst possible pain) administered to each patient verbally at visit #1 and visit #2. The data below shows number of patients with pain score 1 or greater in each group.</description>
        <time_frame>24 to 48 hours (visit #1) and 5 to 7 days (visit #2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5mg Intravitreal Injection</title>
            <description>Intravitreal injection of Ranibizumab 0.5mg once
Ranibizumab 0.5mg: Patient will receive intravitreal injection of Ranibizumab 0.5mg.</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept 2.0mg Intravitreal Injection</title>
            <description>Intravitreal Aflibercept 2.0mg once
Aflibercept 2.0mg: Patients will receive intravitreal injection of Aflibercept 2.0mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Post Injection Pain Score of One or Higher on Pain Scale</title>
          <description>Pain score rated on an 11 point numerical rating from 0-10 ( 0 = no pain, and 10 = worst possible pain) administered to each patient verbally at visit #1 and visit #2. The data below shows number of patients with pain score 1 or greater in each group.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with pain score 1 or higher at visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with pain score 1 or higher at visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab 0.5mg Intravitreal Injection</title>
          <description>Intravitreal injection of Ranibizumab 0.5mg once
Ranibizumab 0.5mg: Patient will receive intravitreal injection of Ranibizumab 0.5mg.</description>
        </group>
        <group group_id="E2">
          <title>Aflibercept 2.0mg Intravitreal Injection</title>
          <description>Intravitreal Aflibercept 2.0mg once
Aflibercept 2.0mg: Patients will receive intravitreal injection of Aflibercept 2.0mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anterior chamber inflammation at Visit 1</sub_title>
                <description>All patients in this group had 0.5+ inflammation as reported using Standardization of Uveitis Nomenculature working group classification.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Anterior chamber inflammation at Visit 2</sub_title>
                <description>Patient had 1+ inflammation as reported using Standardization of Uveitis Nomenculature working group classification.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vitreous inflammation at Visit 1</sub_title>
                <description>Inflammation was mild and was graded as 0.5 on Nussenblatt scale</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vitreous inflammation at Visit 2</sub_title>
                <description>Inflammation was mild and was graded as 0.5 on Nussenblatt scale</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size. Non-randomized choice of medications.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Arshad Khanani M.D., Vitreo-Retinal Diseases and Surgery</name_or_title>
      <organization>Sierra Eye Associates</organization>
      <phone>775-329-0286</phone>
      <email>arshad.khanani@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

